2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
7
Dermatologic
7
Head & Neck
4
Sarcoma
3
Thoracic
2
Lymphoid
2
Gastrointestinal
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Temozolomide
623
Radiotherapy
411
Bevacizumab
257
Magnetic Resonance Spectroscopy
227
Cyclophosphamide
179
Radiosurgery
163
Carboplatin
160
Etoposide
132
Radiation
129
Vincristine
115
Irinotecan
115
Cisplatin
103
Filgrastim
100
Specimen Handling
90
Nivolumab
88
pembrolizumab
84
Surgical Procedures, Operative
83
Lomustine
83
Topotecan
73
Doxorubicin
61
Melphalan
59
Carmustine
57
Radiotherapy, Intensity-Modulated
56
sargramostim
53
Isotretinoin
53
Peripheral Blood Stem Cell Transplantation
52
Granulocyte Colony-Stimulating Factor
51
Chemotherapy, Adjuvant
51
Blood Specimen Collection
51
Erlotinib Hydrochloride
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
bempegaldesleukin
×
CNS
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts